(Q30226968)

11 June 2017

title

Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine (English)

1 reference

influenza A virus subtype H1N1

11 June 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20848866

reference URL

15 July 2024

author name string

Toshiaki Ihara

1

1 reference

11 June 2017

language of work or name

Japanese

0 references

publication date

1 June 2010

1 reference

full work available at URL

11 June 2017

https://www.jstage.jst.go.jp/article/jsv/60/1/60_1_69/_pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20848866

reference URL

15 July 2024

1 reference

11 June 2017

volume

60

1 reference

11 June 2017

issue

1

1 reference

11 June 2017

page(s)

69-78

1 reference

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

11 June 2017

cites work

1

1 reference

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009

15 July 2024

3

1 reference

Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues

15 July 2024

4

1 reference

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

15 July 2024

6

1 reference

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

15 July 2024

7

1 reference

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

15 July 2024

11

1 reference

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

15 July 2024

12

1 reference

Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and direct

15 July 2024

13

1 reference

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

15 July 2024

14

1 reference

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

15 July 2024

15

1 reference

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

15 July 2024

16

1 reference

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

15 July 2024

17

1 reference

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

15 July 2024

18

1 reference

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

15 July 2024

19

1 reference

Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.

15 July 2024

21

1 reference

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

15 July 2024

23

1 reference

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

15 July 2024

24

1 reference

Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine

15 July 2024

25

1 reference

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

15 July 2024

26

1 reference

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

15 July 2024

27

1 reference

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

15 July 2024

28

1 reference

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

15 July 2024

31

1 reference

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

15 July 2024

32

1 reference

Response to a monovalent 2009 influenza A (H1N1) vaccine.

15 July 2024

33

1 reference

A novel influenza A (H1N1) vaccine in various age groups.

15 July 2024

34

1 reference

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

15 July 2024

35

1 reference

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

15 July 2024

36

1 reference

Prevalence of Antibody to Current Influenza Viruses and Effect of Vaccination on Antibody Response

15 July 2024

40

1 reference

15 July 2024

Identifiers

DOI

10.2222/JSV.60.69

1 reference

11 June 2017

1 reference